ライフサイエンスコーパス: standard of care

1 nrolled 478 patients (232 in One4All, 246 in standard of care).

2 , compared with sputum smear microscopy (the standard of care).

3 lls or placebo (control), in addition to the standard of care.

4 25 mg, or placebo once daily in addition to standard of care.

5 actor IX protein (rhFIX) that is the current standard of care.

6 val in the relapsed setting over the current standard of care.

7 hese guidelines are not intended to impose a standard of care.

8 riority trial outcomes compared with current standard of care.

9 ime to progression and could be considered a standard of care.

10 by the addition of maintenance lapatinib to standard of care.

11 (1:1) to either the One4All intervention or standard of care.

12 ed 1:1 to treatment with FCM for 24 weeks or standard of care.

13 benefits and cost savings than the observed standard of care.

14 6 h, respectively, compared to those for the standard of care.

15 ork Heart Association improved on FCM versus standard of care.

16 gimens to a baseline reflective of continued standard of care.

17 th dose de-escalation or discontinuation per standard of care.

18 e similar to retention rates for the current standard of care.

19 level <7%) is an established, cost-effective standard of care.

20 Currently, wide local excision (WLE) is the standard of care.

21 For decades, surgical treatment has been the standard of care.

22 40,000 IU subcutaneously once a week or best standard of care.

23 compare two or more interventions within the standard of care.

24 ceived treatment consistent with the current standard of care.

25 e asthma is poorly controlled by the current standard of care.

26 inflammation beyond current guideline-based standard of care.

27 rkflow were compared to those of the routine standard of care.

28 sive approach to management than the current standard of care.

29 more QALYs (by 0.42) than with the observed standard of care.

30 y Surgery Study-regimen can be regarded as a standard of care.

31 ation with cisplatin+pemetrexed, the current standard of care.

32 a were voluntarily reported according to the standard of care.

33 increase survival, and cannot be considered standard of care.

34 proves this estimation and may present a new standard of care.

35 tients who will not benefit from the current standard of care.

36 released much earlier than with the current standard of care.

37 tabine 60 mg/m(2) in a 5-day schedule versus standard of care.

38 tenance if virologically suppressed; and (4) standard of care: 3-drug regimen of DTG/ABC/3TC.

39 nts (366 compounds with 417 participants) or standard-of-care (318 compounds with 353 participants) C

40 atment recipients compared with the observed standard of care (54.3% initiate opioid use disorder tre

41 e 300 mg or 600 mg intravenous zanamivir, or standard-of-care (75 mg oral oseltamivir) twice a day fo

42 sis focuses on recommendations from the 2017 Standards of Care about monitoring and pharmacologic app

43 We compared this treatment with the standard of care, active surveillance, in men with low-r

44 concurrent and adjuvant temozolomide is the standard of care after biopsy or resection of newly diag

45 e, an extended lymphadenectomy should be the standard of care after nCRT.

46 erior efficacy of a new agent over a current standard-of-care agent is routinely feasible only when e

47 olled trial of EBVs plus standard of care or standard of care alone (SoC).

48 f 35 patients (37%) who received the current standard of care alone and in 8 of 36 patients (22%) who

49 standard of care was superior to the current standard of care alone was 91.2%, falling short of the p

50 ng moisture-retentive occlusive dressing, or standard of care alone.

51 IVST distribution mechanisms compared to the standard of care among female sex workers (FSWs) in Zamb

52 We evaluated the performance of standard of care and 2 new data-derived MI risk estimati

53 etinal procedural trends, which may indicate standard of care and importance of developing methods of

54 etinal procedural trends, which may indicate standard of care and importance of developing methods of

55 parts 1 and 2, patients received supportive standard of care and initiated eltrombopag or placebo at

56 antation with adequate cell dose remains the standard of care and leads to low TRM.

57 V (vCP1521) and AIDSVAX B/E] and the current standard of care and proposes that engineered expression

58 This review covers standards of care and current clinical trials for childr

59 ave already entered the clinic, becoming new standards of care and transforming the prognosis for man

60 wly published data in the context of current standard of care, and provide a comprehensive review and

61 le size, number of patients treated with the standard of care, and the average time to treatment disc

62 c methods, evidentiary basis for the current standards of care, and investigational approaches to tre

63 ence and did not reflect current evidence or standards of care, and the exclusion was therefore lifte

64 ieve pathologic complete response (pCR) from standard-of-care anthracycline/taxane (ACT) chemotherapy

65 ls of peritonitis, even in mice treated with standard-of-care antibiotherapy.

66 Unlike a standard of care antibiotic vancomycin, predatory bacter

67 ains in adjunctive therapy with meropenem, a standard-of-care antibiotic, confirming the importance o

68 Following their response to standard-of-care antibiotics, patients in cohort 1 were

69 have tested twice for HIV than those in the standard of care arm (RR 1.51, 95% CI 1.29-1.77, p < 0.0

70 ely to have tested for HIV than those in the standard of care arm, both at 1 month (risk ratio [RR] 1

71 had sought medical care for HIV than in the standard of care arm, but these differences were not sig

72 79.8% for the coupon arm, and 75.1% for the standard-of-care arm (delivery versus standard of care R

73 m, 84.4% in the coupon arm, and 88.5% in the standard-of-care arm (delivery versus standard of care r

74 ly lower in the 2 HIVST arms compared to the standard-of-care arm.

75 radiosurgery should be considered one of the standards of care as a less toxic alternative to WBRT fo

76 rial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less t

77 011 to 2025: chemoimmunotherapy (CIT) as the standard of care before 2014, oral targeted therapies fo

78 Standard-of-care biological treatment of schizophrenia r

79 approaches have the potential to enhance the standard of care by decreasing infusion frequency to inc

80 Prospective studies comparing current standard-of-care carrier screening with expanded carrier

81 imaging revealed synergy between PDT and the standard-of-care chemotherapeutic carboplatin that evolv

82 t clinical subtype that is resistant to many standard of care chemotherapeutics such as cisplatin.

83 ements upon the therapeutic index of current standard-of-care chemotherapies in preclinical models of

84 thyltransferase inhibitor guadecitabine or a standard-of-care chemotherapy regimen selected by the tr

85 umors had significantly better survival with standard-of-care chemotherapy than patients whose tumors

86 nt-derived xenografts and sensitized them to standard-of-care chemotherapy.

87 2:1 ratio, to receive either blinatumomab or standard-of-care chemotherapy.

88 on, lay counsellor follow-up home visits, or standard-of-care clinic referral, and then (1:1) either

89 counsellor visits than in those who received standard-of-care clinic referral.

90 ment with BRAF and MEK inhibitors aligned to standard-of-care combination therapy, suggesting these r

91 It was produced by the Standards of Care Committee of the British Society of Al

92 that will be responsive to widely registered standard-of-care comparator antibiotics.

93 ple Micronutrient Preparation (UNIMMAP)], or standard of care comprising CSB+ and iron and folic acid

94 The current standard of care, consisting of surgery, radiation and c

95 label extension (OLE) trials that included a standard-of-care control group.

96 h HF were studied and received FCM (n=86) or standard of care (control group, n=86).

97 randomisation via restricted web platform to standard of care (control) or early, goal-directed mobil

98 Upon exposure to standard-of-care cytotoxic drugs or epigenetic modifiers

99 IC phenotypes, rendering cells vulnerable to standard-of-care cytotoxic therapies.

100 nts with SS/SS were managed according to the standard of care, data were prospectively collected.

101 that are limited to interventions within the standard of care do not need to obtain research consent

102 as a single agent or in combination with the standard-of-care drug carboplatin, ND-646 markedly suppr

103 tly defines the response of nine patients to standard-of-care drugs according to their clinical diagn

104 Compared with standard of care, eculizumab specifically abrogated this

105 f either mepolizumab 100 mg or placebo, plus standard of care, every 4 weeks for 24 weeks (the final

106 ferative neoplasm (MPN) for which no current standard of care exists.

107 mcitabine and capecitabine should be the new standard of care following resection for pancreatic duct

108 Both groups otherwise received the same standard of care for a 2-week screening period before ra

109 cal therapies that may potentially alter the standard of care for a disease that has largely been tre

110 Docetaxel treatment should become part of standard of care for adequately fit men commencing long-

111 ation of chemotherapy and trastuzumab is the standard of care for adjuvant treatment of human epiderm

112 urther support the use of pembrolizumab as a standard of care for advanced melanoma.

113 d with mepolizumab or placebo in addition to standard of care for at least 24 weeks.

114 sion patterns of proteins and is part of the standard of care for cancer diagnosis and prognosis, but

115 he inappropriate use of topical therapy, the standard of care for causes of cicatrising conjunctiviti

116 he HIV-1 viral load in plasma is the current standard of care for clinical monitoring of HIV-infected

117 ncer is suspected, tissue biopsy remains the standard of care for diagnosis.

118 Endoscopy is the standard of care for emergency patient evaluation after

119 rapy (nCRT) followed by surgery has become a standard of care for esophageal adenocarcinoma (EAC).

120 rapy (nCRT) followed by surgery has become a standard of care for esophageal adenocarcinoma (EAC).

121 in 37 fractions and is recommended as a new standard of care for external-beam radiotherapy of local

122 lthough trastuzumab plus chemotherapy is the standard of care for first-line treatment of HER2-positi

123 These data support the use of MAC as the standard of care for fit patients with acute myeloid leu

124 Aromatase inhibitors are a standard of care for hormone receptor-positive locally a

125 ed by total mesorectal excision (TME) is the standard of care for locally advanced rectal cancer.

126 en receptor modulator (SERM), represents the standard of care for many patients; however, 30-50% deve

127 l cystectomy (RC) currently is viewed as the standard of care for muscle-invasive bladder cancer (MIB

128 Current standard of care for muscle-invasive urothelial cell car

129 atment recipients compared with the observed standard of care for patients presenting with opioid use

130 understand if CBCT imaging should become the standard of care for patients requiring dental implants.

131 become increasingly necessary to deliver the standard of care for patients with advanced cancer.

132 ocol (SHARP) trial, sorafenib has become the standard of care for patients with advanced unresectable

133 acting antiviral agents (DAAs) represent the standard of care for patients with hepatitis C virus (HC

134 Autologous HCT is now the standard of care for patients with HIV-related lymphomas

135 ti-HIV products can substantively change the standard of care for patients with HIV/AIDS.

136 ransarterial chemoembolisation (TACE) is the standard of care for patients with intermediate stage he

137 Cabazitaxel and prednisone remains the standard of care for patients with metastatic castration

138 Peri-operative chemotherapy and surgery is a standard of care for patients with resectable oesophagog

139 lonal antibody approved as add-on therapy to standard of care for patients with severe eosinophilic a

140 herapy, and might represent a new first-line standard of care for PD-L1-expressing, advanced NSCLC.

141 sistant to gemcitabine, the chemotherapeutic standard of care for PDAC.

142 ce with daily inhaled corticosteroids is the standard of care for persistent asthma.

143 ethotrexate with intercalated surgery is the standard of care for resectable OS in those younger than

144 icate that ruxolitinib could be considered a standard of care for second-line therapy in this post-hy

145 ne oxygenation (ECMO) has long served as the standard of care for short-term mechanical circulatory s

146 el lymph node biopsy (SLNB) is currently the standard of care for staging the axilla in patients with

147 Update Committee recommends that the current standard of care for supportive care and pain management

148 aggressive medical management has become the standard of care for symptomatic patients with intracran

149 Bendamustine plus rituximab is a standard of care for the management of patients with rel

150 ing homes were randomised to a facility-wide standard of care for the residents of either high dose o

151 The current standard of care for the treatment of hepatitis C virus

152 Vancomycin is the standard of care for the treatment of invasive methicill

153 along with concomitant chemoradiotherapy, a standard of care for the treatment of locally advanced h

154 Immunosuppressive therapy is the standard of care for these diseases.

155 rvival improvement and should not be part of standard of care for this population.

156 The results define standard of care for this population.

157 Current standard of care for trigeminal neuralgia is treatment w

158 Platinum-based chemotherapy doublets are a standard of care for women with ovarian cancer recurring

159 ing versus placebo could be considered a new standard of care for women with platinum-sensitive ovari

160 An emerging standard-of-care for long-QT syndrome uses clinical gene

161 astuzumab is combined with chemotherapy as a standard-of-care for newly diagnosed HER2(+) breast canc

162 trolled, double-blind trial of a statin with standard-of-care for patients with cancer, specifically

163 s as set forth in the seventh edition of the Standards of Care for the Health of Transsexual, Transge

164 safety of these new strategies with current standards of care for the prevention or treatment of thr

165 onths in the EPO and 17.4 months in the best standard of care group (HR, 1.057; 95% CI, 0.949 to 1.17

166 One4All group compared with 115 (47%) in the standard-of-care group (Cox proportional hazard ratio 0.

167 thin 6 months versus 108 (34%) of 321 in the standard-of-care group (Cox proportional multivariable h

168 ion group (n=204 [87%]) than in the enhanced standard-of-care group (n=128 [56%]; adjusted odds ratio

169 ion group (n=150 [64%]) than in the enhanced standard-of-care group (n=98 [43%]; 4.13, 2.80-6.11; p<0

170 within 30 days versus 63 (26%) of 246 in the standard-of-care group (odds ratio 19.94, 95% CI 3.86-10

171 ervention group vs one [<1%] in the enhanced standard-of-care group), sexual assault (four [2%] vs on

172 ntervention group versus six in the enhanced standard-of-care group; adverse effects included domesti

173 self-tests in a healthcare facility, or (3) standard of care HIV testing.

174 HIVST from a health clinic/pharmacy), or (3) standard-of-care HIV testing.

175 Because there is no established standard of care, I discuss currently available options

176 s analyses are intended to be conducted with standard of care images, it is conceivable that conversi

177 he images were evaluated against the current standard of care, images acquired with a 3D TSE short in

178 s recurrent PCa with sensitivity superior to standard-of-care imaging at serum prostate-specific anti

179 te superior detection efficacy compared with standard-of-care imaging.

180 ed) showed that the addition of docetaxel to standard of care improved survival.

181 omparing an initial coronary CTA strategy to standard of care in acute chest pain patients.

182 Intravenous rituximab is the standard of care in B-cell non-Hodgkin lymphoma, and is

183 ic profiling is widely predicted to become a standard of care in clinical oncology, but more effectiv

184 atients with MIS treated with MMS or WLE per standard of care in dermatology and surgery (general sur

185 Glucocorticoid treatment is recommended as a standard of care in Duchenne muscular dystrophy; however

186 -modality treatment is widely considered the standard of care in early-stage Hodgkin lymphoma (HL), a

187 xon 11 mutation and should be considered the standard of care in GIST patients treated with neoadjuva

188 Oral favipiravir was part of the current standard of care in Guinea.

189 text message) interventions were superior to standard of care in improving adherence in both the glob

190 nCRT is increasingly standard of care in LAEC, with pCR a surrogate for excel

191 Concurrent chemoradiotherapy is the standard of care in limited-stage small-cell lung cancer

192 100 mg/m(2) given once every 3 weeks is the standard of care in locally advanced head and neck squam

193 ials, and the radial approach has become the standard of care in patients with ACS undergoing angiogr

194 mRDT should be considered as part of the standard of care in patients with BSIs.

195 b as a favourable add-on treatment option to standard of care in patients with severe eosinophilic as

196 rdiovascular Outcomes With Alogliptin Versus Standard of Care in Patients With Type 2 Diabetes Mellit

197 ria using Giemsa-stained blood smears is the standard of care in resource-limited settings.

198 E prophylaxis with LMWH or UH is the current standard of care in TBI.

199 Purpose Gemcitabine is standard of care in the adjuvant treatment of resectable

200 Quantification of HIV-1 RNA has become the standard of care in the clinical management of HIV-1-inf

201 rventions (1.28, 1.01-1.71) were superior to standard of care in the global network; none of the inte

202 peak VO2 was observed on FCM, compared with standard of care in the primary analysis, this effect wa

203 id-fast-stained sputum smears is the current standard of care in the United States to determine airbo

204 ABPM and cardiac structure evaluation as the standard of care in these patients.

205 therapy should continue to be considered the standard of care in this setting.

206 (PD-L1) inhibitors to docetaxel, the current standard of care in this setting.

207 ical coherence tomography (OCT) has become a standard-of-care in retinal imaging.

208 es but also chemotherapy and radiotherapy as standards of care in the oncology clinic.

209 ngle FT by enema with oral vancomycin taper (standard of care) in adult patients experiencing acute r

210 The enhanced standard of care included one clinic-based counselling s

211 hyperacute treatment has led to the current standard of care: intravenous thrombolysis with tissue-t

212 srespect and abuse by changing the norms and standards of care is a potential strategy to improve the

213 se advances that promise to improve upon the standard-of-care lupus nephritis treatments.

214 r up to 4 weeks delivered in an intensive or standard-of-care manner.

215 decision-making by systematically analyzing standard-of-care medical images.

216 reated with cyclophosphamide superior to the standard of care, mesna or nicotinamide-induced DNA deme

217 monitoring and dose adjustment over current standard-of-care metrics without such monitoring remains

218 to dermatology consultation (n = 40) versus standard of care (n = 32).

219 the Amagugu intervention (n=235) or enhanced standard of care (n=229).

220 2, 2016 (delivery, N = 316; coupon, N = 329; standard of care, N = 320); 20% had never tested for HIV

221 clearance over compound I and efavirenz, the standard of care NNRTI.

222 (via minimisation) allocated men 2:1:1:1 to standard of care only (SOC-only; control), standard of c

223 d for patients allocated to the control arm (standard-of-care only) of the STAMPEDE Trial between Oct

224 neck, these data support nivolumab as a new standard-of-care option in this setting.

225 2:1 randomized controlled trial of EBVs plus standard of care or standard of care alone (SoC).

226 in a 1:1 ratio to receive either the current standard of care or the current standard of care plus th

227 ing rejection prophylaxis with eculizumab or standard of care (plasma exchange and intravenous Ig) at

228 ard of care plus zoledronic acid (SOC + ZA), standard of care plus docetaxel (SOC + Doc), or standard

229 the current standard of care or the current standard of care plus three intravenous infusions of ZMa

230 f 36 patients (22%) who received the current standard of care plus ZMapp.

231 o standard of care only (SOC-only; control), standard of care plus zoledronic acid (SOC + ZA), standa

232 ntral venous catheter insertion has become a standard of care, postinsertion chest radiograph remains

233 cutaneous coronary intervention has become a standard-of-care procedure over the past 40 years.

234 th an aCT1 gel formulation plus conventional standard of care protocols, involving moisture-retentive

235 ng hormone therapy (HT) either alone or with standard-of-care radiotherapy (RT) is not well documente

236 re SCD adults at risk of early death despite standard-of-care, randomized 3:2 to THU-decitabine versu

237 CL2 and MCL3 trials, which represent current standard-of-care regimens.

238 s that are promoted by obtaining consent for standard-of-care research and the barriers to obtaining

239 Current standard-of-care results in a marginal therapeutic outco

240 in the standard-of-care arm (delivery versus standard of care risk ratio [RR] = 1.07, 95% CI 0.99-1.1

241 7, 95% CI 0.99-1.15, P = 0.10; coupon versus standard of care RR = 0.95, 95% CI 0.86-1.05, P = 0.29;

242 1, 95% CI 0.98-1.27, P = 0.11; coupon versus standard of care RR = 1.06, 95% CI 0.92-1.22, P = 0.42;

243 or the standard-of-care arm (delivery versus standard of care RR = 1.11, 95% CI 0.98-1.27, P = 0.11;

244 The addition of docetaxel to standard of care should be considered standard care for

245 TV) with or without (+/-) ritonavir (RTV) or standard of care (SOC) (tenofovir disoproxil fumarate 30

246 E) is a leading cause of readmission despite standard of care (SOC) associated with microbial dysbios

247 ation intervention strategy (CIS) versus the standard of care (SOC) on the primary outcome of linkage

248 were randomized to evolocumab, 420 mg, plus standard of care (SOC) or SOC alone.

249 Patients and Methods Standard of care (SOC) was hormone therapy continuously

250 porting penicillin allergy in 3 periods: (1) standard of care (SOC), (2) penicillin skin testing (ST)

251 randomly assigned to provide the CIS or the standard of care (SOC).

252 ocated to TEG-guided transfusion strategy or standard of care (SOC; 1:1 TEG:SOC).

253 The standard of care (SOC; biannual CD4) was the comparator.

254 andomized study, we evaluated oral FA/RIF vs standard-of-care (SOC) intravenous antibiotics for treat

255 of two POC technologies against the current standard-of-care (SOC) laboratory-based assay in South A

256 and Methods Thirty-four patients undergoing standard-of-care (SOC) MR imaging with concomitant CT we

257 Each patient underwent standard-of-care (SOC) triple-site testing, and swabs we

258 The previous standard of care, sofosbuvir/simeprevir or sofosbuvir/pe

259 e issue lies on the poor tolerability of the standard of care soluble iron salts, leading to non-comp

260 ificant clinical benefit in PFS and ORR over standard-of-care sunitinib as first-line therapy in pati

261 ially higher HCV testing rates compared with standard-of-care testing (26.9% versus 1.4% for repeated

262 d in an increase in BC testing compared with standard-of-care testing but also increased costs.

263 for each of the interventions compared with standard-of-care testing.

264 therapeutic strategy superior to the current standard of care that will reduce fractures for patients

265 apy an attractive alternative to the current standards of care that are limited to managing disease s

266 For the 2017 Standards of Care, the ADA Professional Practice Committ

267 Today, anti-angiogenesis agents represent standard-of-care therapies for multiple types of cancers

268 an multiple myeloma cell lines to a gamut of standard-of-care therapies.

269 atment; the median survival is 16 mo despite standard-of-care therapies.

270 test the efficacy of new therapies against a standard of care, thereby assigning a large proportion o

271 In addition to establishing a new standard of care, these two articles pose a number of im

272 io also was simulated where CIT remained the standard of care throughout.

273 The standard of care to enhance long-term survival and stabi

274 Whole brain radiotherapy (WBRT) is the standard of care to improve intracranial control followi

275 Furthermore, this study supports current standard of care to pursue a nonocular biopsy of normal-

276 Standard of care treatment (including lactulose and ceft

277 patients with HGSOC undergoing heterogeneous standard of care treatment.

278 ed administration of these agents became the standard-of-care treatment for this disease.

279 erogeneity of treatments administered; thus, standard-of-care treatment is currently nonspecific for

280 Current standard-of-care treatment of chronically infected hepat

281 , cabozantinib should be considered as a new standard-of-care treatment option for previously treated

282 There are no standard-of-care treatment options for patients with rel

283 severe or difficult-to-treat asthma despite standard-of-care treatment.

284 specially for patients for whom conventional standard-of-care treatments have failed.

285 Standard-of-care treatments using DNA-targeted therapy (

286 y appropriate way to obtain consent for many standard-of-care trials in the emergency setting.

287 strong reason to obtain research consent for standard-of-care trials in the emergency setting.

288 otes the goals for consent in the context of standard-of-care trials.

289 pagliflozin 25 mg, or placebo in addition to standard of care until at least 691 patients experienced

290 either the Amagugu intervention or enhanced standard of care, using a computerised algorithm based o

291 italization for adverse events compared with standard-of-care VKA plus DAPT.

292 rior probability that ZMapp plus the current standard of care was superior to the current standard of

293 rdiovascular Outcomes With Alogliptin Versus Standard of Care) was a phase IIIb clinical outcomes tri

294 The Standards of Care were reviewed and approved by the Exec

295 he uniform 99th percentile should remain the standard of care when using hs-cTnT levels for the diagn

296 ndard of care plus docetaxel (SOC + Doc), or standard of care with both zoledronic acid and docetaxel

297 The controls received the standard of care with IS use 10 times every hour while a

298 tandard of care with or without docetaxel or standard of care with or without bisphosphonates for men

299 , unpublished, and ongoing) comparing either standard of care with or without docetaxel or standard o

300 ll salvage use (intervention) versus current standard of care without routine salvage use (control) i